Get in Touch

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - The RNA Revolution: Unleashing the Therapeutic Potential of RNAi

Stonegate Healthcare's research approach centers on conducting a thorough comparative analysis to identify potentially revolutionary assets and technologies.
Key Takeaways
  • The report covers over 30 companies, highlighted companies include Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ) among others.
  • The report covers the major areas of RNA therapeutics highlighting innovative and undervalued companies focused on developing RNAi, mRNA, and Aptamer technologies.
Dallas, TX - July 12, 2023 - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in RNA Therapeutics. The report, The RNA Revolution: Unleashing the Therapeutic Potential of RNAi, highlights the potential of RNA therapeutics and companies leveraging RNAi technologies are in particular focus as we believe this will be a meaningful area of development.
Other companies highlighted in the report represent various areas of RNA therapeutics, namely mRNA and aptamers. This thematic report will serve as the foundation for Stonegate Healthcare's ongoing market intelligence in RNA therapeutics, providing valuable insights for investors and companies.
For further information or to obtain a FREE copy of the full report, please contact our research team - alamgir@stonegateinc.com 

About Stonegate Healthcare
The Stonegate Healthcare mission is to accelerate meaningful innovations in healthcare through Strategy, Market Intelligence, Business Development, and Investor Outreach. The firm's research approach revolves around conducting comprehensive comparative analyses in specific medical fields in order to identify assets and technologies with the highest disruptive potential. Stonegate Healthcare builds on its foundational thematic research by continuously gathering market intelligence, enabling a current understanding of emerging disruptive technologies.

Key Takeaways
  • The report covers over 30 companies, highlighted companies include Alnylam, Ionis, Laronde, TME Pharma, and Transcode Therapeutics (NASDAQ: RNAZ) among others.
  • The report covers the major areas of RNA therapeutics highlighting innovative and undervalued companies focused on developing RNAi, mRNA, and Aptamer technologies.
Media Gallery
Related Bios
Shiv Kapoor
Managing Partner at Stonegate Healthcare Partners
View Full Bio>>
Alamgir Singh Kandhari
Research Analyst at Stonegate Healthcare Partners
View Full Bio>>
Contacts
Shiv Kapoor
Shiv@stonegateinc.com
Stonegate Healthcare Partners
info@stonegateinc.com
(214) 987-4121
General